Drug Channels

JULY 29, 2022

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. healthcare spending.

Pharmacy 98

Pharmacy Drugs Government Pharmaceuticals 98

The Pharma Data

NOVEMBER 1, 2021

It further evolves Boehringer Ingelheim’s commitments and significantly increases the company’s impact on health, society, and environmental issues, in alignment with the United Nations 2030 Sustainable Development Goals. Boehringer Ingelheim’s commitment to MORE GREEN is underscored by a series of initiatives.

Therapies 52

Therapies Pharmaceuticals International Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 12, 2020

Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030 sets out global targets and actions to align and re-focus the work of countries, partners and stakeholders during. 2030 road map targets. now have the consensus and the commitment of every country to work in.

Disease 52

Disease Government Treatment 52

Antidote

AUGUST 2, 2022

Not only does it impact many people today, but its prevalence is expected to double by 2030. Mitral valve regurgitation is a common kind of heart disease in the United States.

Disease 98

Disease 98

The Pharma Data

FEBRUARY 22, 2021

By 2030, Bayer aspires to reach gender parity on each individual management level. Moreover, Bayer strives to increase the proportion of people with disabilities in the workforce to more than 5 percent by 2030. In Germany, for example, it is currently 4.5

Compliance 52

Compliance Regulations Science Production 52

biobide

DECEMBER 1, 2023

Cannabis derivatives In 2022 the global legal cannabis market was valued at USD 22.1 This is forecasted to grow rapidly, with a growth rate of 25.5% A Key contributing factor to this significant growth prediction is the accelerating legalization of cannabis products and the growing acceptance of its use in the medical field and consumer goods.

Treatment 97

Treatment Production Marketing Research 97

SCIENMAG: Medicine & Health

NOVEMBER 7, 2023

Brussels, 8 November 2023 – New international research on the economic burden of urinary incontinence reveals that the cost of continence care will reach an estimated €69.1 billion in 2023.

International 80

International Production Research 80

The Pharma Data

FEBRUARY 22, 2021

By 2030, Bayer aspires to reach gender parity on each individual management level. Moreover, Bayer strives to increase the proportion of people with disabilities in the workforce to more than 5 percent by 2030. In Germany, for example, it is currently 4.5

Compliance 40

Compliance Regulations 40

The Pharma Data

MAY 31, 2022

The initiative is supported by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase global adoption of biosimilar medicines by at least 30% in 30+ countries by 2030.

Biosimilars 52

Biosimilars Treatment Government Hospitals 52

The Pharma Data

OCTOBER 25, 2021

It further evolves Boehringer Ingelheim’s commitments and significantly increases the company’s donation to appreciatively impacting health, societal and environmental issues, in alignment with the United Nations 2030 Sustainable Development Goals.

Vaccine 52

Vaccine Hospitals Disease Treatment 52

The Pharma Data

NOVEMBER 15, 2020

16, 2020 /PRNewswire/ — Diadem srl , a company developing the first blood-based test for the prediction of early onset Alzheimer’s disease, today announced that it has been selected as a finalist for both the Gaetano Marzotto Company Prize and the Gaetano Marzotto 2030 Social Impact Special Prize. . MILAN , Nov.

Disease 40

Disease Treatment Production Clinical Trials 40

The Pharma Data

MAY 1, 2023

In response, WHO, together with global partners and experts, took the leadership in developing a global strategy that sets forth a vision and roadmap to defeat meningitis by 2030. In November 2020, this global roadmap on meningitis was approved by the Seventy-Third World Health Assembly (resolution WHA73.9).

Treatment 40

Treatment Government Vaccine International 40

SCIENMAG: Medicine & Health

JUNE 13, 2023

Although there are numerous projects from governments, NGOs, and private corporations who are committed to providing safely managed water and sanitation by 2030, a new study advocates for more holistic evaluation of water, sanitation, and hygiene (WASH) interventions. According to the study by Justin Stoler, associate […]

Government 68

Government 68

thought leadership

JUNE 4, 2024

The HTAR will take effect in January 2025 for oncology and/or advanced therapy medicinal product (ATMP) therapies, with other therapies following a staggered implementation process, including orphan drugs in 2028 and all drugs in 2030.

Therapies 59

Therapies Regulations Production Marketing 59

Agency IQ

FEBRUARY 23, 2024

NANCY SKINNER has updated a bill she introduced in early January 2024 to ban the sale of intentionally added PFAS in the state after 2030. BY WALKER LIVINGSTON, ESQ California state Sen. Although the bill may receive state support, the actual implementation of the ban, if passed, would be a herculean task.

59

59

biobide

NOVEMBER 20, 2023

projected by the year 2030. Background on the Cosmetics industry In 2022, the value of the global cosmetics market was estimated to be worth USD 262.21 billion, with an annual growth of 4.2%

Packaging 64

Packaging Regulations Production Marketing 64

Drug Target Review

SEPTEMBER 21, 2023

A novel drug, will be needful at this point as it will; help promote WHO’s roadmap for 2021-2030, provide much effective drugs and equal access to healthcare- as people living with onchocercomas will no longer worry about surgical removal of them. Visualise a society free from the inconvenience and pain associated with river blindness.

Drugs 105

Drugs Treatment Disease Research 105

Drug Target Review

SEPTEMBER 22, 2023

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

The Pharma Data

NOVEMBER 2, 2020

Setting sights on 2030. Despite setbacks due to COVID-19, WHO will accelerate work to achieve this target by 2030. This goal is aligned with the aims of universal health coverage to leave no one behind by 2030. Infections have been brought to such low levels in some areas that 649.1

Packaging 52

Packaging Disease Treatment Drugs 52

The Pharma Data

APRIL 12, 2022

per person per year from now until 2030. This investment would realize more than US$ 230 billion in economic and societal benefits and avert nearly 10 million heart attacks and strokes globally by 2030. NCDs are largely preventable and treatable, nearly 7 million lives could be saved for just US$ 0.84

International 52

International Disease Government Treatment 52

The Pharma Data

NOVEMBER 12, 2020

Committee A, which focuses on programme and budget matters, decided to recommend the adoption of the first-ever resolution on meningitis, which would approve a global roadmap to defeat meningitis by 2030 – a disease that kills 300,000 people annually and leaves one in five of those affected with devastating long-term consequences.

Disease 52

Disease Treatment 52

LifeSciVC

JANUARY 16, 2024

Naturally many of these acquisitions are driven by enthusiasm for clinical-stage assets that may contribute meaningfully to revenues in 2030+, and we are seeing Pharma build deeply in several key areas (obesity, immunology, oncology, neuro) as they add on to existing franchises or build new ones.

Small Molecule 140

Small Molecule Trials Therapies Disease 140

LifeSciVC

APRIL 26, 2024

Fourth, the venture exit environment circa 2027-2030 for the new crop of early stage startups being created today will likely have structural supply/demand elements more favorable than the backdrop in recent years. Fewer startups over time should ameliorate this crowding dynamic to some extent.

DNA 112

DNA Science Marketing Clinical Trials 112

The Pharma Data

JUNE 26, 2021

Sanofi Aims for Carbon Neutrality Sanofi has committed to reduce its greenhouse gas emissions by 55% by 2030 in line with limiting global warming to 1.5°C C and is aiming for carbon neutrality by 2050.

Packaging 52

Packaging Vaccine Production Science 52

The Pharma Data

MAY 26, 2023

The report is part of the NCDs Global Action Plan 2023-2030 and is an update from 2017 and is core to the Implementation Roadmap on NCDs. The latest revision was updated to reflect WHO’s recommendations and guidance and the latest scientific evidence on impact.

Disease 52

Disease Government Treatment Production 52

Agency IQ

MAY 10, 2024

BY RAYAN BHARGAVA, MSC | MAY 9, 2024 11:03 PM CDT Regulatory background Until recently, the EU had plans to halve pesticide reduction by 2030. In late October 2023, the French government announced yet another version: Ecophyto 2030. However, intense farmer protests led the French government to pause Ecophyto 2030 indefinitely. [

Government 40

Government Regulations Production Marketing 40

The Pharma Data

SEPTEMBER 16, 2020

In addition, Novartis further strengthened its carbon neutrality target to aim for full carbon neutrality across its supply chain (Scope 1, 2, 3) by 2030. Novartis recently set new ambitious targets to increase patient reach in low- and middle-income countries by 2025. Our approach to Environmental, Social and Governance topics.

Government 52

Government 52

The Pharma Data

MARCH 11, 2021

Roche is committed to helping countries scale up HIV elimination programs and reach the WHO 2030 goals of 95% of people living with HIV knowing their HIV status; 95% of HIV-positive people on treatment; and 95% of people on treatment having suppressed viral loads. About the cobas Plasma Separation Card.

Disease 52

Disease Treatment Laboratories Virus 52

Drug Target Review

NOVEMBER 15, 2023

The generational shift as Gen-Z enter and move up the workforce, who are expected to comprise 58 percent of the global workforce by 2030, is accelerating the introduction of these new technologies.

Pharmacokinetics 105

Pharmacokinetics International Laboratories Drugs 105

The Pharma Data

DECEMBER 15, 2020

The 2030 Consulting team provides high-caliber tactical contracting and strategic consulting for all aspects of business-to-business software solutions, from software sales and vendor selection to application development, implementation and managed services. Download the whitepaper at: [link].

Science 52

Science Compliance Regulations FDA 52

The Pharma Data

NOVEMBER 5, 2020

Since May, Member States have adopted a number of decisions – the Immunization Agenda 2030, the Decade of Healthy Ageing 2020-2030, as well as initiatives to tackle cervical cancer, tuberculosis, eye care, food safety, intellectual property and influenza preparedness.

International 52

International Compliance Virus Vaccine 52

Drug Target Review

DECEMBER 4, 2023

What’s more, investment in this sector is predicted to rise by 70 percent by 2030. According to the Personalised Medicine Coalition , 34 percent of all new drugs approved by the US Food and Drug Administration (FDA) in 2022 are personalised medicines.

Treatment 105

Treatment Science DNA Doctors 105

The Pharma Data

APRIL 7, 2021

In this context, Sanofi, the only pharmaceutical company that keeps developing and supplying treatments for African trypanosomiasis or sleeping sickness, has committed itself alongside the WHO to eliminate this neglected tropical disease in humans by 2030. Zero plastic packaging for vaccines and ecodesign of products.

Vaccine 52

Vaccine Packaging Disease Treatment 52

DrugBank

AUGUST 9, 2024

In 2021, an estimated 537 million adults were living with diabetes, a number projected to reach 643 million by 2030. billion by 2030. Similarly, the diabetes market is experiencing substantial growth due to the rising prevalence of this chronic condition. The market for cardiovascular drugs, valued at 155.6

Pharmaceuticals 76

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 76

Fierce BioTech

SEPTEMBER 6, 2024

In the coming period, pharma should witness an ongoing transformation, as exclusivity rights to 569 medications valued at $278 billion (2022 sales) are set to expire by 2029/2030.

Marketing 52

Marketing Drugs 52

The Pharma Data

OCTOBER 23, 2020

Delivering Universal Health Coverage 2030 was launched in 2019. . . In the past 20 years, countries have invested heavily in preparing for terrorist attacks, but relatively little in preparing for the attack of a virus – which, as the COVID-19 pandemic has proven, can be far more deadly, disruptive and costly.” . Source link.

Virus 52

Virus Government 52

The Pharma Data

JUNE 28, 2023

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival.

Science 40

Science Government 40